MENU
Updates from LinkedIn follow-us

Blog

  • You are here
  • Home
  • Entrepreneurship
  • David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs
David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs
  • 06
  • 04
  • 2021

David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs

Sharing news of an inspirational relationship with Maxwell Biosciences – supporting the development of a new class of antiviral drugs. This news release includes a link to newly published, peer-reviewed research findings showing potent antiviral activity of Maxwell antimicrobial peptoids. View the press release HERE